Market Overview

4Front to open for adult-use sales at its Chicago dispensary

Share:

Mission South Shore will open at 6 a.m. on Jan. 1, 2020

VANCOUVER and PHOENIX, AZ, Dec. 19, 2019 /CNW/ - 4Front Ventures Corp. (CSE:FFNT) (OTCQX:FFNTF) ("4Front" or the "Company") is pleased to announce that its Mission dispensary located in Chicago's South Shore neighborhood will begin adult-use sales on Jan. 1, 2020.

4Front's logo (CNW Group/4Front)

Mission South Shore is scheduled to open at 6 a.m. and make one of Illinois' first legal adult-use cannabis sales to Edie Moore, executive director of the Chicago chapter of the National Organization for the Reform of Marijuana Laws (NORML) and a positive force for the normalization of cannabis.

The Mission dispensary, located at 8554 S. Commercial Ave., will be the only cannabis retail store on the city's Southeast Side. It has been serving its neighborhood as a medical cannabis dispensary since 2017.

"The opening will be a great moment for our company, Chicago, and Illinois," said Kris Krane, president of 4Front and Mission, and a Chicago resident. "We are honored to be part of it, and also honored to serve Edie, who has worked tirelessly to bring an end to cannabis prohibition, as our first customer."

He added: "We've served the South Shore neighborhood for more than two years and we look forward to continuing to serve our medical patients as we welcome new legal adult customers to our store." 

About 4Front Ventures Corp.
4Front is a cannabis company designed for long-term success and built upon battle-tested operating capabilities at scale, experienced and committed leadership, a strategic asset base, and a commitment to being a magnet for talent. From plant genetics to the cannabis retail experience, 4Front's team applies expertise across the value chain. 4Front has invested heavily to assemble a comprehensive collection of management skills and hands-on operating expertise to capitalize on the unique growth opportunity being afforded by the increased legalization of cannabis. For more information, visit 4Front's website.

This news release was prepared by management of 4Front Ventures, which takes full responsibility for its contents. The Canadian Securities Exchange ("CSE") has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in 4Front Ventures' periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of 4Front Ventures, developments with respect to legislative developments in the United States and the proposed trading dated of the resulting issuer.

Although 4Front Ventures has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under U.S. federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. 4Front Ventures disclaims any intention or obligation to update or revise such information, except as required by applicable law, and 4Front Ventures does not assume any liability for disclosure relating to any other company mentioned herein.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/4front-to-open-for-adult-use-sales-at-its-chicago-dispensary-300977347.html

SOURCE 4Front

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/19/c2919.html

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com